The short answer
A valerian root or rhizome product may add to valproate-related drowsiness, but the plant species must be confirmed. Most cited guidance covers Valeriana officinalis and cannot identify every product labeled Radix et Rhizoma Valerianae.
What this answer covers
Generic valerian root/rhizome node. Apply V. officinalis evidence only when that species and relevant plant part are verified; other species and blends are not automatically equivalent.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- valproate
Confirm the botanical first
Radix et Rhizoma Valerianae describes valerian root and rhizome material without resolving every commercial product. NIH guidance here covers Valeriana officinalis only. Ask the supplier or pharmacist to confirm the botanical species, plant part and preparation rather than relying on the word valerian alone.
Why added drowsiness is possible
For confirmed V. officinalis preparations, NIH guidance describes potential additive sedation and advises against combining valerian with sedatives. Valproate can cause drowsiness and impaired coordination. This supports a conditional precaution, not a proven effect for every generic root product.
A valproate trial has limits
A single-blind migraine study in 84 women added valerian capsules to sodium valproate and reported improvements in migraine measures. The available abstract does not adequately describe the plant part or extraction and does not report a sedation endpoint. Completing the study does not establish that the combination cannot cause drowsiness.
Review before adding it
Bring the product label and complete medicine list to the treating team. No evidence here establishes a safe separation interval or a valproate dose adjustment. If new sleepiness or unsteadiness develops, seek advice and avoid driving while impaired. Do not stop valproate abruptly.
Evidence and practical considerations
Side effects & toxicity
Generic root/rhizome identity is not established as V. officinalis in every product; related sodium-valproate trial abstract lacks sedation assessment. A narrower verified-species precaution is retained separately.
- Exact scope
- Generic valerian root/rhizome node. Apply V. officinalis evidence only when that species and relevant plant part are verified; other species and blends are not automatically equivalent. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Conditional identity bridge only when the product is confirmed as V. officinalis root/rhizome.
Cannot identify the species of Radix et Rhizoma Valerianae in an unspecified product or establish a valproate interaction.
Source 4: original randomized single-blind trial abstract
openurl.ebsco.com · Source check Sep 10, 2026
Population: 84 women with migraine, 42 per group.
Reported fewer, shorter and less intense migraine attacks with valerian; all participants completed the study.
How this applies: Related botanical evidence with direct sodium-valproate exposure; incomplete botanical preparation match to the generic root/rhizome node.
Abstract names V. officinalis but does not adequately characterize plant part/extraction or report a sedation endpoint. Does not identify every generic valerian root product or establish safe co-use.
Research assessment: · Open full citations ↗
Side effects & toxicity
Individual added drowsiness is possible; use the preparation-specific evidence and medical supervision rather than treating the combination as proven toxic or safe.
- Exact scope
- Generic valerian root/rhizome node. Apply V. officinalis evidence only when that species and relevant plant part are verified; other species and blends are not automatically equivalent. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- For generic valerian, applies only after confirming V. officinalis identity; migraine abstract does not assess sedation.
Factors that may matter: Exact preparation; Age; Other sedatives.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Source 3: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Conditional identity bridge only when the product is confirmed as V. officinalis root/rhizome.
Cannot identify the species of Radix et Rhizoma Valerianae in an unspecified product or establish a valproate interaction.
Source 4: original randomized single-blind trial abstract
openurl.ebsco.com · Source check Sep 10, 2026
Population: 84 women with migraine, 42 per group.
Reported fewer, shorter and less intense migraine attacks with valerian; all participants completed the study.
How this applies: Related botanical evidence with direct sodium-valproate exposure; incomplete botanical preparation match to the generic root/rhizome node.
Abstract names V. officinalis but does not adequately characterize plant part/extraction or report a sedation endpoint. Does not identify every generic valerian root product or establish safe co-use.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared article with direct-study limits, preparation boundaries and claim-specific conclusions. | |
| Research summary published |
Article revision: 8cdd649382555d5c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.